Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

4 evidence topics · 3 sources

Natural history and mortality

“39% of these subjects (23/59) have died.” (opens the source at this quote in a new tab)

“Causes of death included severe lactic acidosis, respiratory failure, and infection.” (opens the source at this quote in a new tab)

Age at death and mortality by sex

“Of these, 91% (21/23) died before age 4 years, 61% (14/23) before 1 year, and 43% (10/23) before 3 months.” (opens the source at this quote in a new tab)

“56% of males died compared with 25% of females.” (opens the source at this quote in a new tab)

“Neonatal or infant onset of symptoms was associated with poor outcomes. Males with PDHA1 mutations and low fibroblast PDC activity were less likely to survive beyond infancy.” (opens the source at this quote in a new tab)

Swedish population-based cohort: mortality

“Eight patients (15%) died during the study period.” (opens the source at this quote in a new tab)

Additional genotype, phenotype, and natural-history evidence

“Data from 891 individuals (45% unpublished) were included.” (opens the source at this quote in a new tab)